Back-to-back papers in the June 22, 2023, issue of Nature have identified separate molecular mechanisms underlying sex-specific cancer outcomes. Researchers from The University of Texas MD Anderson Cancer Center showed that increased expression of the epigenetic enzyme KDM5D, which is located on the Y chromosome, contributed to cancer progression in KRAS-mutated tumors. In the same issue of Nature, a team from Cedars-Sinai reported new insights into the consequences of losing the entire Y chromosome.
Interius Biotherapeutics Inc. has reported preclinical data demonstrating the potential of its lead program to generate biologically active chimeric antigen receptor (CAR) cells directly in vivo for the treatment of B-cell malignancies.
Replay Holdings LLC and The University of Texas MD Anderson Cancer Center have announced that the FDA has cleared the IND application for NY-ESO-1 TCR/IL-15 NK, an engineered T-cell receptor natural killer (TCR-NK) cell therapy for advanced synovial sarcoma and myxoid/round cell liposarcoma.
TG Immunopharma Co. Ltd. has announced clearance by the FDA for a clinical trial of TGI-6, a bispecific antibody targeting unique tumor-associated antigens (TAA) and CD3 molecules simultaneously, for solid tumors.
Researchers from Innate Pharma SA recently presented preclinical data for IPH-6501, a novel CD20-targeting tetraspecific antibody-based natural killer (NK)-cell engager therapeutic being developed for the treatment of patients with B-cell non-Hodgkin lymphoma (B-NHL).
Along with preliminary first-in-human data, investigators from F-star Therapeutics Inc. recently presented preclinical results for the tetravalent bispecific antibody FS-222, which targets PD-L1 and CD137 and is being developed for the treatment of advanced treatment-refractory solid tumors.
Alentis Therapeutics AG has received FDA clearance of the company’s IND application for ALE.C04, a first-in-class monoclonal antibody developed to specifically target exposed Claudin-1 (CLDN1) on cancer cells.
Colorectal cancer (CRC) is one of the digestive tract cancers with the highest prevalence. Cancer immunotherapy for CRC brings substantial benefit to patients, but the development of resistance mechanisms and relapsing processes along with immune escape call for new treatment options.
Researchers from Imperial College of Science, Technology and Medicine have reported results of preclinical evaluation of THEO-260, a novel oncolytic virus for the treatment of stromal-rich tumors. The candidate is currently in development for late-stage relapsed refractory ovarian cancer.
RSS
